Advertisement

Wiener Medizinische Wochenschrift

, Volume 157, Issue 13–14, pp 356–361 | Cite as

St. John's wort: Role of active compounds for its mechanism of action and efficacy

  • Veronika Butterweck
  • Mathias Schmidt
Themenschwerpunkt

Summary

St. John's wort (Hypericum perforatum L., SJW) contains numerous compounds with documented biological activity. Constituents that have stimulated the most interest include the naphthodianthrones hypericin and pseudohypericin, a broad range of flavonoids, and the phloroglucinols hyperforin and adhyperforin. According to the actual state of scientific knowledge the total extract has to be considered as the active substance. Although there are some open questions, the bulk of data suggests that several groups of active compounds are contributing to the antidepressant efficacy of the plant extract.

Keywords

Hypericum perforatum Active constituents Pharmacology Clinical efficacy 

Johanniskraut – Beiträge der Inhaltsstoffe zu Wirkmechanismen und Wirksamkeit

Zusammenfassung

Johanniskraut (Hypericum perforatum L., SJW) enthält viele Verbindungen mit dokumentierter biologischer Aktivität. Zu den Inhaltstoffen, die das größte Interesse ausgelöst haben, zählen die Naphthodianthrone Hypericin und Pseudohypericin, eine große Zahl von Flavonoiden sowie die Phloroglucinole Hyperforin und Adhyperforin. Nach dem aktuellen Stand der wissenschaftlichen Erkenntnisse muss der Gesamtextrakt als der eigentliche Wirkstoff betrachtet werden. Trotz einiger offener Fragen ergibt sich aus der Gesamtdatenlage, dass mehrere Inhaltstoffgruppen zur antidepressiven Wirksamkeit des Pflanzenextraktes beitragen.

Schlüsselwörter

Hypericum perforatum Wirkstoffe Pharmakologie Klinische Wirksamkeit 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Linde K, Mulrow CD, Egger M (2005) St. John's Wort for depression. Cochrane Database Syst Rev: CD000448Google Scholar
  2. Clement K, Covertson CR, Johnson MJ, Dearing K (2006) St. John's wort and the treatment of mild to moderate depression: a systematic review. Holist Nurs Pract 20: 197–203PubMedGoogle Scholar
  3. Butterweck V (2003) Mechanism of action of St. John's wort in depression: what is known? CNS Drugs 17: 539–562PubMedCrossRefGoogle Scholar
  4. Greeson JM, Sanford B, Monti DA (2001) St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl) 153: 402–414CrossRefGoogle Scholar
  5. Mennini T, Gobbi M (2004) The antidepressant mechanism of Hypericum perforatum. Life Sci 75: 1021–1027PubMedCrossRefGoogle Scholar
  6. Nathan PJ (2001) Hypericum perforatum (St. John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychopharmacol 15: 47–54PubMedGoogle Scholar
  7. Sparenberg B, Demisch L, Hölzl J (1993) Untersuchungen über antidepressive Wirkstoffe von Johanniskraut. Pharm Z Wiss 138: 50–54Google Scholar
  8. Berghöfer R, Hölzl J (1986) Johanniskraut (Hypericum perforatum L.) – Prüfung auf Verfälschung. Dtsch Apoth Ztg 47: 2569–2573Google Scholar
  9. Cellarova E, Daxnerova Z, Kimakova K, Haluskova J (1994) The variability of the hypericin content in the regenerants of Hypericum perforatum. Acta Biotechnologica 14: 267–274CrossRefGoogle Scholar
  10. Brantner A, Kartnig TH, Quehenberger F (1994) Vergleichende phytochemische Untersuchungen an Hypericum perforatum L. und Hypericum maculatum Crantz. Scient Pharm 62: 261–276Google Scholar
  11. Beerhues L (2006) Hyperforin. Phytochemistry 67: 2201–2207PubMedCrossRefGoogle Scholar
  12. Melzer M, Fuhrken D, Kolkmann R (1998) Hyperforin im Johanniskraut. Hauptwirkstoff oder nur Leitsubstanz? Dtsch Apoth Ztg 13: 4754–4760Google Scholar
  13. Jürgenliemk G, Nahrstedt A (2002) Phenolic compounds from Hypericum perforatum. Planta Med 68: 88–91PubMedCrossRefGoogle Scholar
  14. Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H (1984) Inhibition of monoamine oxidase by hypericin. Planta Med 50: 272–274PubMedCrossRefGoogle Scholar
  15. Bladt S, Wagner H (1994) Inhibition of MAO by fractions and constituents of hypericum extract. J Geriatr Psychiatry Neurol 7(Suppl 1): 57–59CrossRefGoogle Scholar
  16. Cott JM (1997) In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 30(Suppl 2): 108–112PubMedGoogle Scholar
  17. Thiede H-M, Walper A (1994) Inhibition of MAO and COMT by hypericum extracts and hypericin. J Geriatr Psychiatry Neurol 7: 54–56CrossRefGoogle Scholar
  18. Nielsen M, Frokjaer S, Braestrup C (1988) High affinity of the naturally-occurring biflavonoid, amentoflavon to brain benzodiazepine receptors in vitro. Biochem Pharmacol 37: 3285–3287PubMedCrossRefGoogle Scholar
  19. Baureithel KH, Buter KB, Engesser A, Burkard W, Schaffner W (1997) Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum. Pharm Acta Helv 72: 153–157PubMedCrossRefGoogle Scholar
  20. Butterweck V, Nahrstedt A, Evans J, Hufeisen S, Rauser L, Savage J et al (2002) In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs. Psychopharmacology (Berl) 162: 193–202CrossRefGoogle Scholar
  21. Gobbi M, Moia M, Pirona L, Morizzoni P, Mennini T (2001) In vitro binding studies with two hypericum perforatum extracts – hyperforin, hypericin and biapigenin – on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Pharmacopsychiatry 34(Suppl 1): 45–48CrossRefGoogle Scholar
  22. Raffa RB (1998) Screen of receptor and uptake-site activity of hypericin component of St. John's wort reveals sigma receptor binding. Life Sci 62: L265–L270CrossRefGoogle Scholar
  23. Simmen U, Burkard W, Berger K, Schaffner W, Lundstrom K (1999) Extracts and constituents of Hypericum perforatum inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system. J Recept Signal Transduct Res 19: 59–74PubMedGoogle Scholar
  24. Simmen U, Higelin J, Berger-Büter K, Schaffner W, Lundstrom K (2001) Neurochemical studies with St. John's wort in vitro. Pharmacopsychiatry 34(Suppl 1): 137–142CrossRefGoogle Scholar
  25. Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Müller WE (1998) Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci 63: 499–510PubMedCrossRefGoogle Scholar
  26. Chatterjee SS, Noldner M, Koch E, Erdelmeier C (1998) Antidepressant activity of hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry 31(Suppl 1): 7–15PubMedCrossRefGoogle Scholar
  27. Müller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schäfer C (1998) Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 31(Suppl 1): 16–21PubMedGoogle Scholar
  28. Buchholzer ML, Dvorak C, Chatterjee SS, Klein J (2002) Dual modulation of striatal acetylcholine release by hyperforin, a constituent of St. John's wort. J Pharmacol Exp Ther 301: 714–719PubMedCrossRefGoogle Scholar
  29. Jensen AG, Hansen SH, Nielsen EO (2001) Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci 68: 1593–1605PubMedCrossRefGoogle Scholar
  30. Gobbi M, Valle FD, Ciapparelli C, Diomede L, Morazzoni P, Verotta L et al (1999) Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol 360: 262–269PubMedCrossRefGoogle Scholar
  31. Neary JT, Whittemore SR, Bu Y, Mehta H, Shi YF (2001) Biochemical mechanisms of action of Hypericum LI 160 in glial and neuronal cells: inhibition of neurotransmitter uptake and stimulation of extracellular signal regulated protein kinase. Pharmacopsychiatry 34(Suppl 1): 103–107CrossRefGoogle Scholar
  32. Singer A, Wonnemann M, Müller WE (1999) Hyperforin, a major antidepressant constituent of St. John's wort, inhibits serotonin uptake by elevating free intracellular Na+. J Pharmacol Exp Ther 290: 1363–1368PubMedGoogle Scholar
  33. Wonnemann M, Singer A, Müller WE (2000) Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's wort: the role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacology 23: 188–197PubMedCrossRefGoogle Scholar
  34. Wonnemann M, Singer A, Siebert B, Müller WE (2001) Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John's wort. Pharmacopsychiatry 34: 148–151CrossRefGoogle Scholar
  35. Fisunov A, Lozovaya N, Tsintsadze T, Chatterjee S, Nöldner M, Krishtal O (2000) Hyperforin modulates gating of P-type Ca2+ current in cerebellar Purkinje neurons. Pflügers Arch 440: 427–434PubMedCrossRefGoogle Scholar
  36. Chatterjee S, Filippov V, Lishko P, Maximyuk O, Noldner M, Krishtal O (1999) Hyperforin attenuates various ionic conductance mechanisms in the isolated hippocampal neurons of rat. Life Sci 65: 2395–2405PubMedCrossRefGoogle Scholar
  37. Krishtal O, Lozovaya N, Fisunov A, Tsintsadze T, Pankratov Y, Kopanitsa M et al (2001) Modulation of ion channels in rat neurons by the constituents of Hypericum perforatum. Pharmacopsychiatry 34(Suppl 1): 74–82CrossRefGoogle Scholar
  38. Biber A, Fischer H, Römer A, Chatterjee SS (1998) Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry 31(Suppl 1): 36–43PubMedGoogle Scholar
  39. Butterweck V, Wall A, Liefländer-Wulf U, Winterhoff H, Nahrstedt A (1997) Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity. Pharmacopsychiatry 30(Suppl 2): 117–124PubMedGoogle Scholar
  40. Zanoli P, Rivasi M, Baraldi C, Baraldi M (2002) Pharmacological activity of hyperforin acetate in rats. Behav Pharmacol 13: 645–651PubMedGoogle Scholar
  41. Butterweck V, Christoffel V, Nahrstedt A, Petereit F, Spengler B, Winterhoff H (2003) Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models. Life Sci 73: 627–639PubMedGoogle Scholar
  42. Butterweck V, Jürgenliemk G, Nahrstedt A, Winterhoff H (2000) Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test. Planta Med 66: 3–6PubMedCrossRefGoogle Scholar
  43. Butterweck V, Korte B, Winterhoff H (2001) Pharmacological and endocrine effects of Hypericum perforatum and hypericin after repeated treatment. Pharmacopsychiatry 34(Suppl 1): 2–7CrossRefGoogle Scholar
  44. Butterweck V, Hegger M, Winterhoff H (2004) Flavonoids of St. John's wort reduce HPA axis function in the rat. Planta Med 70: 1008–1011PubMedCrossRefGoogle Scholar
  45. Butterweck V, Winterhoff H, Herkenham M (2001) St. John's wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats. Mol Psychiatry 6: 547–564PubMedCrossRefGoogle Scholar
  46. Gambarana C, Ghiglieri O, Tolu P, De Montis MG, Giachetti D, Bombardelli E et al (1999) Efficacy of an Hypericum perforatum (St. John's wort) extract in preventing and reverting a condition of escape deficit in rats. Neuropsychopharmacology 21: 247–257PubMedCrossRefGoogle Scholar
  47. Butterweck V, Petereit F, Winterhoff H, Nahrstedt A (1998) Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Med 64: 291–294PubMedCrossRefGoogle Scholar
  48. Jürgenliemk G, Nahrstedt A (2003) Dissolution, solubility and cooperativity of phenolic compounds from Hypericum perforatum L. in aqueous systems. Pharmazie 58: 200–203PubMedGoogle Scholar
  49. Nöldner M, Schötz K (2002) Rutin is essential for the antidepressant activity of Hypericum perforatum extracts in the forced swimming test. Planta Med 68: 577–580PubMedCrossRefGoogle Scholar
  50. Butterweck V, Liefländer-Wulf U, Winterhoff H, Nahrstedt A (2003) Plasma levels of hypericin in presence of procyanidin B2 and hyperosidea pharmacokinetic study in rats. Planta Med 69: 189–192PubMedCrossRefGoogle Scholar
  51. Schulz HU, Schürer M, Bässler D, Weiser D (2005) Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multipe oral dosing of a Hypericum extract containing tablet. Arzneim-Forsch/Drug Res 55: 15–22Google Scholar
  52. Müller SC, Uehleke B, Wöhling H, Petzsch M, Majcher-Peszynska J, Hehl EM et al. (2004) Effect of St. John's wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther 75: 546–557CrossRefGoogle Scholar
  53. Laakmann G, Schüle C, Baghai T, Kieser M (1998) St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 31(Suppl 1): 54–59PubMedGoogle Scholar
  54. Hoffmann J, Kühl ED (1979) Therapie von depressiven Zuständen mit Hypericin. ZFA (Stuttgart) 55: 776–782Google Scholar
  55. Schlich D, Braukmann F, Schenk N (1987) Behandlung depressiver Zustandsbilder mit Hypericinum. Psycho 13: 440–447Google Scholar
  56. Schmidt U, Schenk N, Schwarz I, Vorberg G (1989) Hypericin-Applikation. Zur Therapie depressiver Verstimmungen. Psycho 15: 665–671Google Scholar
  57. Schrader E, Meier B, Brattström A (1998) Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study. Hum Psychopharmacol 13: 163–169CrossRefGoogle Scholar
  58. Schrader E (2000) Equivalence of St. John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 15: 61–68PubMedGoogle Scholar
  59. Woelk H (2000) Comparison of St. John's wort and imipramine for treating depression: randomised controlled trial. Br Med J 321: 536–539CrossRefGoogle Scholar
  60. Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V (2006) Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol 62: 255–233CrossRefGoogle Scholar
  61. Gutmann H, Poller B, Buter KB, Pfrunder A, Schaffner W, Drewe J (2006) Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression? Planta Med 72: 685–690PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Department of Pharmaceutics, College of PharmacyUniversity of FloridaGainesvilleUSA
  2. 2.HerbresearchTussenhausenGermany

Personalised recommendations